Dysregulation of gene expression in the R6/2 model of polyglutamine disease: Parallel changes in muscle and brain

Human Molecular Genetics

Volumn 11, Issue 17, 2002, Pages 1911-1926

  Luthi Carter, Ruth ^a   Hanson, Sarah A ^a   Strand, Andrew D ^b   Bergstrom, Donald A ^b   Chun, Wanjoo ^b   Peters, Nikki L ^a   Woods, Annette M ^a   Chan, Edmond Y ^c   Kooperberg, Charles ^b   Krainc, Dimitri ^a   Young, Anne B ^a   Tapscott, Stephen J ^b   Olson, James M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP; HUNTINGTIN; MESSENGER RNA; MUTANT PROTEIN; POLYGLUTAMINE; RETINOIC ACID; HD PROTEIN, HUMAN; HDH PROTEIN, MOUSE; NERVE PROTEIN; NUCLEAR PROTEIN; PEPTIDE;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; BRAIN CORTEX; BRAIN REGION; CEREBELLUM; CLINICAL FEATURE; CONTROLLED STUDY; CORPUS STRIATUM; DISORDERS OF AMINO ACID AND PROTEIN METABOLISM; DNA MICROARRAY; FEMALE; GENE EXPRESSION REGULATION; GENE INDUCTION; HUNTINGTON CHOREA; INTERNET; MALE; MOUSE; MUTATIONAL ANALYSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOLOGY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; SYMPTOMATOLOGY; UNINDEXED SEQUENCE; ANIMAL; BRAIN; DISEASE MODEL; ENZYME IMMUNOASSAY; GENETICS; HUMAN; METABOLISM; MOLECULAR GENETICS; NORTHERN BLOTTING; TRANSGENIC MOUSE; WESTERN BLOTTING;

ANIMALIA; EUKARYOTA;

ANIMALS; BASE SEQUENCE; BLOTTING, NORTHERN; BLOTTING, WESTERN; BRAIN; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; HUMANS; HUNTINGTON DISEASE; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, TRANSGENIC; MOLECULAR SEQUENCE DATA; MUSCLE, SKELETAL; NERVE TISSUE PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; RNA, MESSENGER;

EID: 0037101835     PISSN: 09646906     EISSN: None     Source Type: Journal    
DOI: 10.1093/hmg/11.17.1911     Document Type: Article

References (62)

1. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
2. Huntington's disease: Lessons from and for molecular neuroscience
3. Recent advances on the pathogenesis of Huntington's disease
4. Widespread expression of the human and rat Huntington's disease gene in brain and nonneuronal tissues
5. Widespread expression of Huntington's disease gene (IT15) protein product
6. Huntington's disease gene: Regional and cellular expression in brain of normal and affected individuals
7. Trinucleotide repeats in neurogenetic disorders
8. Polyglutamine pathogenesis
9. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice
10. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract
11. Mutant huntingtin expression in clonal striatal cells: Dissociation of inclusion formation and neuronal survival by caspase inhibition
12. Tissue-specific proteolysis of Huntingtin (htt) in human brain: Evidence of enhanced levels of N- and C-terminal htt fragments in Huntington's disease striatum
13. Caspase 3-cleaved N-terminal fragments of wild-type and mutant huntingtin are present in normal and Huntington's disease brains, associate with membranes, and undergo calpain-dependent proteolysis
14. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation
15. Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation
16. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation
17. Progressive formation of inclusions in the striatum and hippocampus of mice transgenic for the human Huntington's disease mutation
18. Nuclear and neuropil aggregates in Huntington's disease: Relationship to neuropathology
19. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease
20. Neuropathological classification of Huntington's disease
21. Huntington disease
22. Formation of polyglutamine inclusions in non-CNS tissue
23. Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes
24. Abnormalities in the functioning of adipocytes from R6/2 mice that are transgenic for the Huntington's disease mutation
25. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease
26. The Huntington's disease protein interacts with p53 and CREB-binding protein and represses transcription
27. CREB-binding protein sequestration by expanded polyglutamine
28. Interference by huntingtin and atrophin-1 with cbp-mediated transcription leading to cellular toxicity
29. Expanded polyglutamine stretches interact with TAFII130, interfering with CREB-dependent transcription
30. Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
31. Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease
32. Sp1 and TAFII130 transcriptional activity disrupted in early huntington's disease
33. Estimating the statistical significance of gene expression changes observed with oligonucleotide arrays
34. Integrated genomic and proteomic analyses of a systematically perturbed metabolic network
35. Tissue transglutaminase does not contribute to the formation of mutant huntingtin aggregates
36. Neurological abnormalities in a knock-in mouse model of Huntington's disease
37. Huntington's disease
38. Polyglutamine and transcription: Gene expression changes shared by DRPLA and Huntington's disease mouse models reveal context-independent effects
39. Increased huntingtin protein length reduces the number of polyglutamine-induced gene expression changes in mouse models of Huntington's disease
40. Altered transcription in yeast expressing expanded polyglutamine
41. Early transcriptional profiles in huntingtin-inducible striatal cells by microarray analyses
42. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation
43. Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo
44. Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells
45. Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin
46. Polyglutamine and CBP: Fatal attraction?
47. Transcriptional dysregulation in Huntington's disease
48. Expanded polyglutamine stretches lead to aberrant transcriptional regulation in polyglutamine diseases
49. Histone deacetylase inhibitors reduce polyglutamine toxicity
50. Huntington's disease. Exploiting expression
51. Interaction of Huntington disease protein with transcriptional activator Sp1
52. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease
53. Analysis of the role of heat shock protein (Hsp) molecular chaperones in polyglutamine disease
54. Huntingtin expression stimulates endosomal-lysosomal activity, endosome tubulation, and autophagy
55. Dominant phenotypes produced by the HD mutation in STHdh(Q111) striatal cells
56. Inhibition of caspase-1 slows disease progression in a mouse model of Huntington's disease
57. Early alterations in gene expression and cell morphology in a mouse model of Huntington's disease
58. Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease
59. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human Huntington disease gene
60. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease
61. High density synthetic oligonucleotide arrays
62. Promoter-specific regulation of MyoD binding and signal transduction cooperate to pattern gene expression